Waverley Pharma Inc.
WAVE.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 803.91% | -77.09% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 803.91% | -77.09% | -- |
| Cost of Revenue | -- | -- | 152.58% | -89.31% | -- |
| Gross Profit | -- | -- | 496.94% | -41.85% | -- |
| SG&A Expenses | 24.75% | -5.62% | -18.74% | -71.14% | -50.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.99% | 71.03% | 8.32% | -34.51% | -20.23% |
| Operating Income | 103.33% | 91.82% | 77.76% | 20.02% | -32.22% |
| Income Before Tax | 92.02% | 87.19% | 95.25% | 13.41% | -40.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.02% | 87.19% | 95.25% | 13.41% | -40.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.02% | 87.19% | 95.25% | 13.41% | -40.47% |
| EBIT | 103.33% | 91.82% | 77.76% | 20.02% | -32.22% |
| EBITDA | 113.63% | 101.11% | 76.49% | -11.48% | -51.06% |
| EPS Basic | 91.49% | 86.11% | 95.05% | 13.95% | -42.42% |
| Normalized Basic EPS | 93.10% | 86.96% | 84.85% | 14.81% | -38.10% |
| EPS Diluted | 94.52% | 86.11% | 95.05% | 2.67% | -121.21% |
| Normalized Diluted EPS | 93.10% | 86.96% | 84.85% | 14.81% | -38.10% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |